Reference
Li X, et al. Health and economic burden of respiratory syncytial virus (RSV) disease and the cost-effectiveness of potential interventions against RSV among children under 5 years in 72 Gavi-eligible countries. BMC Medicine : 6 Apr 2020. Available from: URL: https://doi.org/10.1186/s12916-020-01537-6
Rights and permissions
About this article
Cite this article
Cost effectiveness of RSV intervention in GAVI-eligible countries. PharmacoEcon Outcomes News 851, 13 (2020). https://doi.org/10.1007/s40274-020-6736-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6736-2